BBA
TBPH icon

Baader Bank Aktiengesellschaft’s Theravance Biopharma TBPH Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,100
Closed -$413K – 545
2025
Q4 		$413K Sell
22,100
-31,400
-59% -$521K 0.03% 335
2025
Q3 		$781K Buy
+53,500
New +$676K 0.05% 208

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baader Bank Aktiengesellschaft's TBPH Position: Q1 2026 in Review

Baader Bank Aktiengesellschaft sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 22,100 shares — an estimated $413K sold.

Baader Bank Aktiengesellschaft first reported a position in TBPH in Q3 2025 and held it in 2 quarters. The position peaked at $781K in Q3 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Baader Bank Aktiengesellschaft reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 22,100 Theravance Biopharma shares in Q1 2026, an estimated $413K.
  • Baader Bank Aktiengesellschaft first reported a position in Theravance Biopharma in Q3 2025 and held it in 2 quarters.
  • Baader Bank Aktiengesellschaft's Theravance Biopharma position peaked at $781K in Q3 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q1 2026, filed 8 May 2026.